Treatment and prognosis of stage I follicular lymphoma in the modern era–does PET matter?

Ohad S. Bentur, Ronit Gurion, Anat Gafter-Gvili, Moshe Gatt, Lev Shvidel, Netanel A. Horowitz, Ron Ram, Yair Herishanu, Nadav Sarid, Ora Paltiel, Chezi Ganzel, Natalia Kreiniz, Najib Dally, Odit Gutwein, Pia Raanani, Irit Avivi, Chava Perry

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma. Patients with stage I disease are usually treated with radiotherapy (RT). In previous studies, mostly from the pre positron emission tomography–computed tomography (PET-CT) era, the 5 year progression-free survival (PFS) and overall survival (OS) rates of stage I disease were 60–80% and 80–93%, respectively. This study retrospectively evaluated the outcome of stage I FL which was treated with involved field RT in the PET-CT era between 2002 and 2015. Ninety-one patients were enrolled. Five year PFS and OS rates were 73% and 97%, respectively. Relapse occurred in 19 (21%) patients, 74% occurring outside the radiation field. In conclusion, PET-CT staging of clinical stage I FL may contribute to the improved prognosis in patients treated with RT compared to historical cohorts, possibly due to better identification of “genuine” stage I disease.

Original languageEnglish
Pages (from-to)1163-1171
Number of pages9
JournalLeukemia and Lymphoma
Volume59
Issue number5
DOIs
StatePublished - 4 May 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

  • Follicular lymphoma
  • immunotherapy
  • positron emission tomography
  • radiotherapy
  • rituximab

Fingerprint

Dive into the research topics of 'Treatment and prognosis of stage I follicular lymphoma in the modern era–does PET matter?'. Together they form a unique fingerprint.

Cite this